can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges
Clicks: 209
ID: 147145
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
5.7
/100
19 views
19 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Drug discovery and development has become longer and costlier process. The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards “me too” drugs and improved generics (505(b) (2)) fillings. The discontinuance of molecules at late stage clinical trials is common these years. The molecules are withdrawn at various stages of discovery and development process for reasons such as poor ADME properties, lack of efficacy and safety reasons. Hence this review focuses on possible applications of formulation and drug delivery to salvage molecules and improve the drugability. The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (108 words).
Try re-searching for a better abstract.
| Reference Key |
s2014actacan
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Basavaraj S;Guru V. Betageri |
| Journal | energy policy |
| Year | 2014 |
| DOI |
10.1016/j.apsb.2013.12.003
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.